nodes	percent_of_prediction	percent_of_DWPC	metapath
Danazol—PGR—corpus luteum—testicular cancer	0.0576	0.116	CbGeAlD
Danazol—SHBG—seminiferous tubule of testis—testicular cancer	0.0542	0.109	CbGeAlD
Danazol—CYP19A1—corpus luteum—testicular cancer	0.0518	0.104	CbGeAlD
Danazol—AR—scrotum—testicular cancer	0.05	0.101	CbGeAlD
Danazol—CYP19A1—seminiferous tubule of testis—testicular cancer	0.0439	0.0884	CbGeAlD
Danazol—AR—seminiferous tubule of testis—testicular cancer	0.0389	0.0783	CbGeAlD
Danazol—SHBG—semen—testicular cancer	0.0299	0.0603	CbGeAlD
Danazol—PGR—Ovarian Infertility Genes—DAZL—testicular cancer	0.0276	0.266	CbGpPWpGaD
Danazol—CYP19A1—semen—testicular cancer	0.0243	0.0489	CbGeAlD
Danazol—AR—semen—testicular cancer	0.0215	0.0433	CbGeAlD
Danazol—CYP19A1—Ovarian Infertility Genes—DAZL—testicular cancer	0.0181	0.174	CbGpPWpGaD
Danazol—CCL2—embryo—testicular cancer	0.0116	0.0233	CbGeAlD
Danazol—CCL2—seminal vesicle—testicular cancer	0.0109	0.0219	CbGeAlD
Danazol—GNRHR—gonad—testicular cancer	0.0101	0.0203	CbGeAlD
Danazol—CCL2—Ectoderm Differentiation—TFAP2C—testicular cancer	0.00854	0.0823	CbGpPWpGaD
Danazol—GNRHR—female gonad—testicular cancer	0.00819	0.0165	CbGeAlD
Danazol—GNRHR—testis—testicular cancer	0.00726	0.0146	CbGeAlD
Danazol—CCL2—female gonad—testicular cancer	0.00639	0.0129	CbGeAlD
Danazol—CCL2—testis—testicular cancer	0.00567	0.0114	CbGeAlD
Danazol—CCL2—Peptide ligand-binding receptors—INSL3—testicular cancer	0.00501	0.0483	CbGpPWpGaD
Danazol—ESR1—embryo—testicular cancer	0.00476	0.00959	CbGeAlD
Danazol—SHBG—gonad—testicular cancer	0.00459	0.00924	CbGeAlD
Danazol—AR—seminal vesicle—testicular cancer	0.00456	0.00917	CbGeAlD
Danazol—CCL2—lymph node—testicular cancer	0.00411	0.00827	CbGeAlD
Danazol—SHBG—female gonad—testicular cancer	0.00373	0.0075	CbGeAlD
Danazol—CYP19A1—gonad—testicular cancer	0.00372	0.00749	CbGeAlD
Danazol—CCL2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00336	0.0324	CbGpPWpGaD
Danazol—PGR—female gonad—testicular cancer	0.00336	0.00676	CbGeAlD
Danazol—SHBG—testis—testicular cancer	0.00331	0.00666	CbGeAlD
Danazol—CCL2—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP2—testicular cancer	0.0033	0.0318	CbGpPWpGaD
Danazol—AR—gonad—testicular cancer	0.00329	0.00663	CbGeAlD
Danazol—ESR1—gonad—testicular cancer	0.00323	0.00651	CbGeAlD
Danazol—GNRHR—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00308	0.0296	CbGpPWpGaD
Danazol—CYP19A1—female gonad—testicular cancer	0.00302	0.00608	CbGeAlD
Danazol—PGR—testis—testicular cancer	0.00298	0.006	CbGeAlD
Danazol—CYP19A1—testis—testicular cancer	0.00268	0.0054	CbGeAlD
Danazol—AR—female gonad—testicular cancer	0.00268	0.00539	CbGeAlD
Danazol—ESR1—female gonad—testicular cancer	0.00263	0.00529	CbGeAlD
Danazol—CCL2—GPCR ligand binding—INSL3—testicular cancer	0.00256	0.0247	CbGpPWpGaD
Danazol—AR—testis—testicular cancer	0.00237	0.00478	CbGeAlD
Danazol—GNRHR—GPCR ligand binding—INSL3—testicular cancer	0.00234	0.0226	CbGpPWpGaD
Danazol—ESR1—testis—testicular cancer	0.00233	0.00469	CbGeAlD
Danazol—ESR1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.00231	0.0223	CbGpPWpGaD
Danazol—PGR—lymph node—testicular cancer	0.00216	0.00435	CbGeAlD
Danazol—CYP19A1—lymph node—testicular cancer	0.00194	0.00391	CbGeAlD
Danazol—ESR1—LKB1 signaling events—STK11—testicular cancer	0.00177	0.0171	CbGpPWpGaD
Danazol—AR—lymph node—testicular cancer	0.00172	0.00346	CbGeAlD
Danazol—ESR1—lymph node—testicular cancer	0.00169	0.0034	CbGeAlD
Danazol—GNRHR—GPCR downstream signaling—INSL3—testicular cancer	0.00132	0.0127	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—INSL3—testicular cancer	0.00131	0.0127	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—INSL3—testicular cancer	0.0012	0.0116	CbGpPWpGaD
Danazol—Oedema—Bleomycin—testicular cancer	0.0011	0.00276	CcSEcCtD
Danazol—Visual impairment—Cisplatin—testicular cancer	0.0011	0.00276	CcSEcCtD
Danazol—Vision blurred—Ifosfamide—testicular cancer	0.00109	0.00273	CcSEcCtD
Danazol—Thrombocytopenia—Bleomycin—testicular cancer	0.00108	0.0027	CcSEcCtD
Danazol—Flushing—Cisplatin—testicular cancer	0.00106	0.00266	CcSEcCtD
Danazol—Vertigo—Ifosfamide—testicular cancer	0.00104	0.0026	CcSEcCtD
Danazol—Leukopenia—Ifosfamide—testicular cancer	0.00103	0.00259	CcSEcCtD
Danazol—Photosensitivity—Methotrexate—testicular cancer	0.00103	0.00259	CcSEcCtD
Danazol—ESR1—Plasma membrane estrogen receptor signaling—MMP2—testicular cancer	0.00103	0.00992	CbGpPWpGaD
Danazol—Oedema—Dactinomycin—testicular cancer	0.00103	0.00258	CcSEcCtD
Danazol—Fluid retention—Doxorubicin—testicular cancer	0.00103	0.00257	CcSEcCtD
Danazol—Asthenia—Chlorambucil—testicular cancer	0.00102	0.00256	CcSEcCtD
Danazol—Palpitations—Ifosfamide—testicular cancer	0.00102	0.00256	CcSEcCtD
Danazol—PGR—Signaling by ERBB4—KITLG—testicular cancer	0.00102	0.0098	CbGpPWpGaD
Danazol—Alopecia—Cisplatin—testicular cancer	0.00101	0.00253	CcSEcCtD
Danazol—ESR1—FOXM1 transcription factor network—MMP2—testicular cancer	0.00101	0.00973	CbGpPWpGaD
Danazol—Pruritus—Chlorambucil—testicular cancer	0.00101	0.00253	CcSEcCtD
Danazol—Thrombocytopenia—Dactinomycin—testicular cancer	0.00101	0.00252	CcSEcCtD
Danazol—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.00101	0.00252	CcSEcCtD
Danazol—Convulsion—Ifosfamide—testicular cancer	0.001	0.00251	CcSEcCtD
Danazol—Hypertension—Ifosfamide—testicular cancer	0.000998	0.0025	CcSEcCtD
Danazol—Erythema multiforme—Etoposide—testicular cancer	0.000991	0.00248	CcSEcCtD
Danazol—Paraesthesia—Bleomycin—testicular cancer	0.000991	0.00248	CcSEcCtD
Danazol—Arthralgia—Ifosfamide—testicular cancer	0.000984	0.00246	CcSEcCtD
Danazol—Flushing—Etoposide—testicular cancer	0.000973	0.00244	CcSEcCtD
Danazol—Hepatic function abnormal—Epirubicin—testicular cancer	0.000972	0.00243	CcSEcCtD
Danazol—Photosensitivity—Epirubicin—testicular cancer	0.000967	0.00242	CcSEcCtD
Danazol—AR—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000961	0.00925	CbGpPWpGaD
Danazol—Visual disturbance—Methotrexate—testicular cancer	0.000958	0.0024	CcSEcCtD
Danazol—Muscle spasms—Cisplatin—testicular cancer	0.000958	0.0024	CcSEcCtD
Danazol—Oedema—Ifosfamide—testicular cancer	0.000943	0.00236	CcSEcCtD
Danazol—Chills—Etoposide—testicular cancer	0.000941	0.00236	CcSEcCtD
Danazol—Vision blurred—Cisplatin—testicular cancer	0.000939	0.00235	CcSEcCtD
Danazol—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.000938	0.00235	CcSEcCtD
Danazol—Asthenia—Vinblastine—testicular cancer	0.000937	0.00235	CcSEcCtD
Danazol—Tremor—Cisplatin—testicular cancer	0.000933	0.00234	CcSEcCtD
Danazol—Alopecia—Etoposide—testicular cancer	0.000926	0.00232	CcSEcCtD
Danazol—Thrombocytopenia—Ifosfamide—testicular cancer	0.000923	0.00231	CcSEcCtD
Danazol—Hyperhidrosis—Ifosfamide—testicular cancer	0.000912	0.00228	CcSEcCtD
Danazol—Vomiting—Chlorambucil—testicular cancer	0.000906	0.00227	CcSEcCtD
Danazol—Hepatic function abnormal—Doxorubicin—testicular cancer	0.000899	0.00225	CcSEcCtD
Danazol—CYP19A1—Biological oxidations—HPGDS—testicular cancer	0.000899	0.00866	CbGpPWpGaD
Danazol—Photosensitivity—Doxorubicin—testicular cancer	0.000895	0.00224	CcSEcCtD
Danazol—Leukopenia—Cisplatin—testicular cancer	0.000892	0.00223	CcSEcCtD
Danazol—Fatigue—Dactinomycin—testicular cancer	0.000887	0.00222	CcSEcCtD
Danazol—Back pain—Etoposide—testicular cancer	0.000883	0.00221	CcSEcCtD
Danazol—Muscle spasms—Etoposide—testicular cancer	0.000877	0.0022	CcSEcCtD
Danazol—Urticaria—Bleomycin—testicular cancer	0.000877	0.00219	CcSEcCtD
Danazol—Body temperature increased—Bleomycin—testicular cancer	0.000872	0.00218	CcSEcCtD
Danazol—Irritability—Methotrexate—testicular cancer	0.000866	0.00217	CcSEcCtD
Danazol—Dizziness—Vinblastine—testicular cancer	0.000864	0.00216	CcSEcCtD
Danazol—Convulsion—Cisplatin—testicular cancer	0.000863	0.00216	CcSEcCtD
Danazol—Mood swings—Methotrexate—testicular cancer	0.00086	0.00215	CcSEcCtD
Danazol—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.000859	0.00215	CcSEcCtD
Danazol—Nausea—Chlorambucil—testicular cancer	0.000847	0.00212	CcSEcCtD
Danazol—Paraesthesia—Ifosfamide—testicular cancer	0.000847	0.00212	CcSEcCtD
Danazol—Anxiety—Cisplatin—testicular cancer	0.000845	0.00212	CcSEcCtD
Danazol—AR—Integrated Breast Cancer Pathway—STK11—testicular cancer	0.000843	0.00811	CbGpPWpGaD
Danazol—Affect lability—Epirubicin—testicular cancer	0.000836	0.00209	CcSEcCtD
Danazol—Migraine—Epirubicin—testicular cancer	0.000836	0.00209	CcSEcCtD
Danazol—Vomiting—Vinblastine—testicular cancer	0.000831	0.00208	CcSEcCtD
Danazol—Vertigo—Etoposide—testicular cancer	0.00082	0.00205	CcSEcCtD
Danazol—Headache—Vinblastine—testicular cancer	0.000818	0.00205	CcSEcCtD
Danazol—Leukopenia—Etoposide—testicular cancer	0.000817	0.00205	CcSEcCtD
Danazol—Body temperature increased—Dactinomycin—testicular cancer	0.000813	0.00204	CcSEcCtD
Danazol—Fatigue—Ifosfamide—testicular cancer	0.000813	0.00204	CcSEcCtD
Danazol—Oedema—Cisplatin—testicular cancer	0.000813	0.00204	CcSEcCtD
Danazol—Constipation—Ifosfamide—testicular cancer	0.000806	0.00202	CcSEcCtD
Danazol—Mood swings—Epirubicin—testicular cancer	0.000805	0.00201	CcSEcCtD
Danazol—Loss of consciousness—Etoposide—testicular cancer	0.000802	0.00201	CcSEcCtD
Danazol—Thrombocytopenia—Cisplatin—testicular cancer	0.000796	0.00199	CcSEcCtD
Danazol—Tachycardia—Cisplatin—testicular cancer	0.000793	0.00199	CcSEcCtD
Danazol—Asthenia—Bleomycin—testicular cancer	0.000792	0.00198	CcSEcCtD
Danazol—Convulsion—Etoposide—testicular cancer	0.000791	0.00198	CcSEcCtD
Danazol—Hypertension—Etoposide—testicular cancer	0.000788	0.00197	CcSEcCtD
Danazol—Hyperhidrosis—Cisplatin—testicular cancer	0.000786	0.00197	CcSEcCtD
Danazol—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—testicular cancer	0.000784	0.00755	CbGpPWpGaD
Danazol—Pruritus—Bleomycin—testicular cancer	0.000781	0.00195	CcSEcCtD
Danazol—Eosinophilia—Methotrexate—testicular cancer	0.000777	0.00194	CcSEcCtD
Danazol—CCL2—Signaling Pathways—INSL3—testicular cancer	0.000776	0.00747	CbGpPWpGaD
Danazol—Nausea—Vinblastine—testicular cancer	0.000776	0.00194	CcSEcCtD
Danazol—Abdominal pain upper—Epirubicin—testicular cancer	0.000776	0.00194	CcSEcCtD
Danazol—Migraine—Doxorubicin—testicular cancer	0.000774	0.00194	CcSEcCtD
Danazol—Affect lability—Doxorubicin—testicular cancer	0.000774	0.00194	CcSEcCtD
Danazol—ESR1—ATF-2 transcription factor network—MMP2—testicular cancer	0.00077	0.00742	CbGpPWpGaD
Danazol—Pancreatitis—Methotrexate—testicular cancer	0.000769	0.00193	CcSEcCtD
Danazol—PGR—Signaling by ERBB4—FGFR3—testicular cancer	0.000756	0.00728	CbGpPWpGaD
Danazol—Urticaria—Ifosfamide—testicular cancer	0.000749	0.00188	CcSEcCtD
Danazol—Body temperature increased—Ifosfamide—testicular cancer	0.000745	0.00187	CcSEcCtD
Danazol—Mood swings—Doxorubicin—testicular cancer	0.000745	0.00186	CcSEcCtD
Danazol—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000741	0.00185	CcSEcCtD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.00074	0.00713	CbGpPWpGaD
Danazol—Asthenia—Dactinomycin—testicular cancer	0.000738	0.00185	CcSEcCtD
Danazol—Paraesthesia—Cisplatin—testicular cancer	0.00073	0.00183	CcSEcCtD
Danazol—Thrombocytopenia—Etoposide—testicular cancer	0.000729	0.00183	CcSEcCtD
Danazol—Tachycardia—Etoposide—testicular cancer	0.000727	0.00182	CcSEcCtD
Danazol—Eosinophilia—Epirubicin—testicular cancer	0.000727	0.00182	CcSEcCtD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—STK11—testicular cancer	0.000725	0.00698	CbGpPWpGaD
Danazol—Hyperhidrosis—Etoposide—testicular cancer	0.00072	0.0018	CcSEcCtD
Danazol—Pancreatitis—Epirubicin—testicular cancer	0.00072	0.0018	CcSEcCtD
Danazol—Abdominal pain upper—Doxorubicin—testicular cancer	0.000718	0.0018	CcSEcCtD
Danazol—Photosensitivity reaction—Methotrexate—testicular cancer	0.000716	0.00179	CcSEcCtD
Danazol—GNRHR—Signaling Pathways—INSL3—testicular cancer	0.00071	0.00684	CbGpPWpGaD
Danazol—Vomiting—Bleomycin—testicular cancer	0.000702	0.00176	CcSEcCtD
Danazol—AR—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000698	0.00672	CbGpPWpGaD
Danazol—Rash—Bleomycin—testicular cancer	0.000696	0.00174	CcSEcCtD
Danazol—Dermatitis—Bleomycin—testicular cancer	0.000695	0.00174	CcSEcCtD
Danazol—PGR—Signaling by ERBB4—KIT—testicular cancer	0.000695	0.00669	CbGpPWpGaD
Danazol—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000693	0.00174	CcSEcCtD
Danazol—Asthenia—Ifosfamide—testicular cancer	0.000677	0.00169	CcSEcCtD
Danazol—Eosinophilia—Doxorubicin—testicular cancer	0.000673	0.00168	CcSEcCtD
Danazol—Sweating—Methotrexate—testicular cancer	0.000671	0.00168	CcSEcCtD
Danazol—Photosensitivity reaction—Epirubicin—testicular cancer	0.00067	0.00168	CcSEcCtD
Danazol—Paraesthesia—Etoposide—testicular cancer	0.000669	0.00167	CcSEcCtD
Danazol—Weight increased—Epirubicin—testicular cancer	0.000668	0.00167	CcSEcCtD
Danazol—Pruritus—Ifosfamide—testicular cancer	0.000667	0.00167	CcSEcCtD
Danazol—Haematuria—Methotrexate—testicular cancer	0.000667	0.00167	CcSEcCtD
Danazol—Pancreatitis—Doxorubicin—testicular cancer	0.000666	0.00167	CcSEcCtD
Danazol—Nausea—Bleomycin—testicular cancer	0.000655	0.00164	CcSEcCtD
Danazol—Vomiting—Dactinomycin—testicular cancer	0.000654	0.00164	CcSEcCtD
Danazol—ESR1—Integrated Breast Cancer Pathway—STK11—testicular cancer	0.000649	0.00625	CbGpPWpGaD
Danazol—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000649	0.00162	CcSEcCtD
Danazol—Rash—Dactinomycin—testicular cancer	0.000649	0.00162	CcSEcCtD
Danazol—Body temperature increased—Cisplatin—testicular cancer	0.000643	0.00161	CcSEcCtD
Danazol—Fatigue—Etoposide—testicular cancer	0.000642	0.00161	CcSEcCtD
Danazol—Jaundice—Epirubicin—testicular cancer	0.000638	0.0016	CcSEcCtD
Danazol—Constipation—Etoposide—testicular cancer	0.000637	0.00159	CcSEcCtD
Danazol—Haemoglobin—Methotrexate—testicular cancer	0.000631	0.00158	CcSEcCtD
Danazol—PGR—Gene Expression—DNMT3L—testicular cancer	0.00063	0.00606	CbGpPWpGaD
Danazol—Haemorrhage—Methotrexate—testicular cancer	0.000628	0.00157	CcSEcCtD
Danazol—Sweating—Epirubicin—testicular cancer	0.000628	0.00157	CcSEcCtD
Danazol—Haematuria—Epirubicin—testicular cancer	0.000624	0.00156	CcSEcCtD
Danazol—Dizziness—Ifosfamide—testicular cancer	0.000624	0.00156	CcSEcCtD
Danazol—Photosensitivity reaction—Doxorubicin—testicular cancer	0.00062	0.00155	CcSEcCtD
Danazol—Weight increased—Doxorubicin—testicular cancer	0.000618	0.00155	CcSEcCtD
Danazol—Nausea—Dactinomycin—testicular cancer	0.000611	0.00153	CcSEcCtD
Danazol—Visual impairment—Methotrexate—testicular cancer	0.000605	0.00152	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.0006	0.0015	CcSEcCtD
Danazol—Vomiting—Ifosfamide—testicular cancer	0.0006	0.0015	CcSEcCtD
Danazol—ESR1—Signaling by ERBB4—KITLG—testicular cancer	0.000597	0.00575	CbGpPWpGaD
Danazol—Rash—Ifosfamide—testicular cancer	0.000595	0.00149	CcSEcCtD
Danazol—Dermatitis—Ifosfamide—testicular cancer	0.000594	0.00149	CcSEcCtD
Danazol—Erythema multiforme—Methotrexate—testicular cancer	0.000594	0.00149	CcSEcCtD
Danazol—Urticaria—Etoposide—testicular cancer	0.000592	0.00148	CcSEcCtD
Danazol—Haemoglobin—Epirubicin—testicular cancer	0.000591	0.00148	CcSEcCtD
Danazol—Jaundice—Doxorubicin—testicular cancer	0.00059	0.00148	CcSEcCtD
Danazol—Body temperature increased—Etoposide—testicular cancer	0.000589	0.00147	CcSEcCtD
Danazol—Haemorrhage—Epirubicin—testicular cancer	0.000588	0.00147	CcSEcCtD
Danazol—Asthenia—Cisplatin—testicular cancer	0.000583	0.00146	CcSEcCtD
Danazol—Sweating—Doxorubicin—testicular cancer	0.000581	0.00145	CcSEcCtD
Danazol—Haematuria—Doxorubicin—testicular cancer	0.000577	0.00145	CcSEcCtD
Danazol—Visual impairment—Epirubicin—testicular cancer	0.000566	0.00142	CcSEcCtD
Danazol—Chills—Methotrexate—testicular cancer	0.000563	0.00141	CcSEcCtD
Danazol—Nausea—Ifosfamide—testicular cancer	0.00056	0.0014	CcSEcCtD
Danazol—Erythema multiforme—Epirubicin—testicular cancer	0.000556	0.00139	CcSEcCtD
Danazol—Alopecia—Methotrexate—testicular cancer	0.000555	0.00139	CcSEcCtD
Danazol—Haemoglobin—Doxorubicin—testicular cancer	0.000546	0.00137	CcSEcCtD
Danazol—Flushing—Epirubicin—testicular cancer	0.000545	0.00137	CcSEcCtD
Danazol—Haemorrhage—Doxorubicin—testicular cancer	0.000544	0.00136	CcSEcCtD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000538	0.00518	CbGpPWpGaD
Danazol—Asthenia—Etoposide—testicular cancer	0.000534	0.00134	CcSEcCtD
Danazol—Back pain—Methotrexate—testicular cancer	0.000529	0.00132	CcSEcCtD
Danazol—Chills—Epirubicin—testicular cancer	0.000527	0.00132	CcSEcCtD
Danazol—Pruritus—Etoposide—testicular cancer	0.000527	0.00132	CcSEcCtD
Danazol—Visual impairment—Doxorubicin—testicular cancer	0.000524	0.00131	CcSEcCtD
Danazol—Alopecia—Epirubicin—testicular cancer	0.000519	0.0013	CcSEcCtD
Danazol—Vomiting—Cisplatin—testicular cancer	0.000517	0.00129	CcSEcCtD
Danazol—Vision blurred—Methotrexate—testicular cancer	0.000515	0.00129	CcSEcCtD
Danazol—Erythema multiforme—Doxorubicin—testicular cancer	0.000514	0.00129	CcSEcCtD
Danazol—Rash—Cisplatin—testicular cancer	0.000513	0.00128	CcSEcCtD
Danazol—Dermatitis—Cisplatin—testicular cancer	0.000512	0.00128	CcSEcCtD
Danazol—Flushing—Doxorubicin—testicular cancer	0.000505	0.00126	CcSEcCtD
Danazol—Tension—Epirubicin—testicular cancer	0.000502	0.00126	CcSEcCtD
Danazol—Nervousness—Epirubicin—testicular cancer	0.000497	0.00124	CcSEcCtD
Danazol—Back pain—Epirubicin—testicular cancer	0.000495	0.00124	CcSEcCtD
Danazol—Dizziness—Etoposide—testicular cancer	0.000492	0.00123	CcSEcCtD
Danazol—Muscle spasms—Epirubicin—testicular cancer	0.000492	0.00123	CcSEcCtD
Danazol—Vertigo—Methotrexate—testicular cancer	0.000491	0.00123	CcSEcCtD
Danazol—Leukopenia—Methotrexate—testicular cancer	0.000489	0.00123	CcSEcCtD
Danazol—Chills—Doxorubicin—testicular cancer	0.000488	0.00122	CcSEcCtD
Danazol—Nausea—Cisplatin—testicular cancer	0.000483	0.00121	CcSEcCtD
Danazol—Vision blurred—Epirubicin—testicular cancer	0.000482	0.00121	CcSEcCtD
Danazol—Alopecia—Doxorubicin—testicular cancer	0.00048	0.0012	CcSEcCtD
Danazol—AR—Gene Expression—DNMT3L—testicular cancer	0.00048	0.00462	CbGpPWpGaD
Danazol—Convulsion—Methotrexate—testicular cancer	0.000474	0.00119	CcSEcCtD
Danazol—Vomiting—Etoposide—testicular cancer	0.000474	0.00119	CcSEcCtD
Danazol—Rash—Etoposide—testicular cancer	0.00047	0.00118	CcSEcCtD
Danazol—Dermatitis—Etoposide—testicular cancer	0.000469	0.00117	CcSEcCtD
Danazol—Headache—Etoposide—testicular cancer	0.000467	0.00117	CcSEcCtD
Danazol—Arthralgia—Methotrexate—testicular cancer	0.000465	0.00117	CcSEcCtD
Danazol—Tension—Doxorubicin—testicular cancer	0.000464	0.00116	CcSEcCtD
Danazol—Nervousness—Doxorubicin—testicular cancer	0.00046	0.00115	CcSEcCtD
Danazol—Vertigo—Epirubicin—testicular cancer	0.00046	0.00115	CcSEcCtD
Danazol—Syncope—Epirubicin—testicular cancer	0.000459	0.00115	CcSEcCtD
Danazol—Leukopenia—Epirubicin—testicular cancer	0.000458	0.00115	CcSEcCtD
Danazol—Back pain—Doxorubicin—testicular cancer	0.000458	0.00115	CcSEcCtD
Danazol—Muscle spasms—Doxorubicin—testicular cancer	0.000455	0.00114	CcSEcCtD
Danazol—Palpitations—Epirubicin—testicular cancer	0.000452	0.00113	CcSEcCtD
Danazol—Loss of consciousness—Epirubicin—testicular cancer	0.00045	0.00113	CcSEcCtD
Danazol—PGR—Signaling Pathways—INSL3—testicular cancer	0.000448	0.00431	CbGpPWpGaD
Danazol—Vision blurred—Doxorubicin—testicular cancer	0.000446	0.00112	CcSEcCtD
Danazol—ESR1—Signaling by ERBB4—FGFR3—testicular cancer	0.000444	0.00428	CbGpPWpGaD
Danazol—Convulsion—Epirubicin—testicular cancer	0.000443	0.00111	CcSEcCtD
Danazol—Nausea—Etoposide—testicular cancer	0.000442	0.00111	CcSEcCtD
Danazol—Hypertension—Epirubicin—testicular cancer	0.000442	0.00111	CcSEcCtD
Danazol—Thrombocytopenia—Methotrexate—testicular cancer	0.000437	0.00109	CcSEcCtD
Danazol—Arthralgia—Epirubicin—testicular cancer	0.000435	0.00109	CcSEcCtD
Danazol—Anxiety—Epirubicin—testicular cancer	0.000434	0.00109	CcSEcCtD
Danazol—Hyperhidrosis—Methotrexate—testicular cancer	0.000431	0.00108	CcSEcCtD
Danazol—Vertigo—Doxorubicin—testicular cancer	0.000425	0.00106	CcSEcCtD
Danazol—Syncope—Doxorubicin—testicular cancer	0.000424	0.00106	CcSEcCtD
Danazol—Leukopenia—Doxorubicin—testicular cancer	0.000424	0.00106	CcSEcCtD
Danazol—Palpitations—Doxorubicin—testicular cancer	0.000418	0.00105	CcSEcCtD
Danazol—Oedema—Epirubicin—testicular cancer	0.000417	0.00105	CcSEcCtD
Danazol—Loss of consciousness—Doxorubicin—testicular cancer	0.000416	0.00104	CcSEcCtD
Danazol—Shock—Epirubicin—testicular cancer	0.000411	0.00103	CcSEcCtD
Danazol—Convulsion—Doxorubicin—testicular cancer	0.00041	0.00103	CcSEcCtD
Danazol—Thrombocytopenia—Epirubicin—testicular cancer	0.000409	0.00102	CcSEcCtD
Danazol—Hypertension—Doxorubicin—testicular cancer	0.000409	0.00102	CcSEcCtD
Danazol—ESR1—Signaling by ERBB4—KIT—testicular cancer	0.000408	0.00393	CbGpPWpGaD
Danazol—Tachycardia—Epirubicin—testicular cancer	0.000407	0.00102	CcSEcCtD
Danazol—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000406	0.00102	CcSEcCtD
Danazol—Hyperhidrosis—Epirubicin—testicular cancer	0.000404	0.00101	CcSEcCtD
Danazol—Arthralgia—Doxorubicin—testicular cancer	0.000403	0.00101	CcSEcCtD
Danazol—Anxiety—Doxorubicin—testicular cancer	0.000402	0.00101	CcSEcCtD
Danazol—Paraesthesia—Methotrexate—testicular cancer	0.000401	0.001	CcSEcCtD
Danazol—Dyspepsia—Methotrexate—testicular cancer	0.000393	0.000983	CcSEcCtD
Danazol—Oedema—Doxorubicin—testicular cancer	0.000386	0.000967	CcSEcCtD
Danazol—Fatigue—Methotrexate—testicular cancer	0.000385	0.000963	CcSEcCtD
Danazol—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.00038	0.000952	CcSEcCtD
Danazol—Shock—Doxorubicin—testicular cancer	0.00038	0.000952	CcSEcCtD
Danazol—Thrombocytopenia—Doxorubicin—testicular cancer	0.000378	0.000947	CcSEcCtD
Danazol—Tachycardia—Doxorubicin—testicular cancer	0.000377	0.000944	CcSEcCtD
Danazol—Paraesthesia—Epirubicin—testicular cancer	0.000375	0.000939	CcSEcCtD
Danazol—Hyperhidrosis—Doxorubicin—testicular cancer	0.000373	0.000935	CcSEcCtD
Danazol—ESR1—Gene Expression—DNMT3L—testicular cancer	0.00037	0.00356	CbGpPWpGaD
Danazol—Dyspepsia—Epirubicin—testicular cancer	0.000367	0.00092	CcSEcCtD
Danazol—Fatigue—Epirubicin—testicular cancer	0.00036	0.000901	CcSEcCtD
Danazol—Constipation—Epirubicin—testicular cancer	0.000357	0.000894	CcSEcCtD
Danazol—Urticaria—Methotrexate—testicular cancer	0.000354	0.000887	CcSEcCtD
Danazol—Body temperature increased—Methotrexate—testicular cancer	0.000353	0.000883	CcSEcCtD
Danazol—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000352	0.000881	CcSEcCtD
Danazol—Paraesthesia—Doxorubicin—testicular cancer	0.000347	0.000868	CcSEcCtD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000345	0.00332	CbGpPWpGaD
Danazol—Dyspepsia—Doxorubicin—testicular cancer	0.00034	0.000851	CcSEcCtD
Danazol—Fatigue—Doxorubicin—testicular cancer	0.000333	0.000834	CcSEcCtD
Danazol—Urticaria—Epirubicin—testicular cancer	0.000332	0.00083	CcSEcCtD
Danazol—Constipation—Doxorubicin—testicular cancer	0.00033	0.000827	CcSEcCtD
Danazol—Body temperature increased—Epirubicin—testicular cancer	0.00033	0.000826	CcSEcCtD
Danazol—CCL2—Metabolism of proteins—MMP2—testicular cancer	0.000321	0.00309	CbGpPWpGaD
Danazol—Asthenia—Methotrexate—testicular cancer	0.00032	0.000801	CcSEcCtD
Danazol—Pruritus—Methotrexate—testicular cancer	0.000316	0.00079	CcSEcCtD
Danazol—Urticaria—Doxorubicin—testicular cancer	0.000307	0.000768	CcSEcCtD
Danazol—Body temperature increased—Doxorubicin—testicular cancer	0.000305	0.000765	CcSEcCtD
Danazol—Asthenia—Epirubicin—testicular cancer	0.0003	0.00075	CcSEcCtD
Danazol—Pruritus—Epirubicin—testicular cancer	0.000295	0.00074	CcSEcCtD
Danazol—Dizziness—Methotrexate—testicular cancer	0.000295	0.000739	CcSEcCtD
Danazol—Vomiting—Methotrexate—testicular cancer	0.000284	0.00071	CcSEcCtD
Danazol—Rash—Methotrexate—testicular cancer	0.000281	0.000704	CcSEcCtD
Danazol—Dermatitis—Methotrexate—testicular cancer	0.000281	0.000704	CcSEcCtD
Danazol—Headache—Methotrexate—testicular cancer	0.000279	0.0007	CcSEcCtD
Danazol—Asthenia—Doxorubicin—testicular cancer	0.000277	0.000694	CcSEcCtD
Danazol—Dizziness—Epirubicin—testicular cancer	0.000276	0.000691	CcSEcCtD
Danazol—Pruritus—Doxorubicin—testicular cancer	0.000273	0.000684	CcSEcCtD
Danazol—Vomiting—Epirubicin—testicular cancer	0.000265	0.000665	CcSEcCtD
Danazol—Nausea—Methotrexate—testicular cancer	0.000265	0.000663	CcSEcCtD
Danazol—Rash—Epirubicin—testicular cancer	0.000263	0.000659	CcSEcCtD
Danazol—Dermatitis—Epirubicin—testicular cancer	0.000263	0.000658	CcSEcCtD
Danazol—ESR1—Signaling Pathways—INSL3—testicular cancer	0.000263	0.00253	CbGpPWpGaD
Danazol—CYP3A4—Biological oxidations—HPGDS—testicular cancer	0.000262	0.00253	CbGpPWpGaD
Danazol—Headache—Epirubicin—testicular cancer	0.000262	0.000655	CcSEcCtD
Danazol—Dizziness—Doxorubicin—testicular cancer	0.000255	0.00064	CcSEcCtD
Danazol—CCL2—Signaling Pathways—H2AFZ—testicular cancer	0.000248	0.00239	CbGpPWpGaD
Danazol—Nausea—Epirubicin—testicular cancer	0.000248	0.000621	CcSEcCtD
Danazol—CCL2—Signaling Pathways—STK11—testicular cancer	0.000247	0.00238	CbGpPWpGaD
Danazol—Vomiting—Doxorubicin—testicular cancer	0.000246	0.000615	CcSEcCtD
Danazol—Rash—Doxorubicin—testicular cancer	0.000244	0.00061	CcSEcCtD
Danazol—Dermatitis—Doxorubicin—testicular cancer	0.000243	0.000609	CcSEcCtD
Danazol—Headache—Doxorubicin—testicular cancer	0.000242	0.000606	CcSEcCtD
Danazol—Nausea—Doxorubicin—testicular cancer	0.000229	0.000574	CcSEcCtD
Danazol—CCL2—Signaling Pathways—KITLG—testicular cancer	0.000229	0.0022	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—H2AFZ—testicular cancer	0.000227	0.00219	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—STK11—testicular cancer	0.000226	0.00218	CbGpPWpGaD
Danazol—PGR—Gene Expression—H2AFZ—testicular cancer	0.00022	0.00212	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—KITLG—testicular cancer	0.000209	0.00201	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—FGFR3—testicular cancer	0.00017	0.00164	CbGpPWpGaD
Danazol—AR—Gene Expression—H2AFZ—testicular cancer	0.000168	0.00162	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—KIT—testicular cancer	0.000156	0.0015	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—FGFR3—testicular cancer	0.000155	0.0015	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—HPGDS—testicular cancer	0.000154	0.00148	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—H2AFZ—testicular cancer	0.000143	0.00138	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—KIT—testicular cancer	0.000143	0.00137	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—STK11—testicular cancer	0.000142	0.00137	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—KITLG—testicular cancer	0.000132	0.00127	CbGpPWpGaD
Danazol—ESR1—Gene Expression—H2AFZ—testicular cancer	0.000129	0.00125	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—STK11—testicular cancer	0.000112	0.00108	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—FGFR3—testicular cancer	9.8e-05	0.000944	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—KIT—testicular cancer	9e-05	0.000866	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—H2AFZ—testicular cancer	8.41e-05	0.00081	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—STK11—testicular cancer	8.36e-05	0.000805	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—KITLG—testicular cancer	7.74e-05	0.000745	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—FGFR3—testicular cancer	5.75e-05	0.000554	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—KIT—testicular cancer	5.28e-05	0.000508	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—HPGDS—testicular cancer	4.49e-05	0.000432	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—STK11—testicular cancer	3.26e-05	0.000314	CbGpPWpGaD
